With US$ 30.46 billion in exports and robust manufacturing capabilities, the industry is poised to expand into high-value drugs while strengthening ESG and compliance standards
Speakers are: Ch. A. P. Rameswara Rao, National President, BDMAI; Dr. Paidi Yella Reddy, Founder, President & CEO, Sapala Organics; K. V. Rama Gopal, Site Manager & Executive Director, Clariant India; Dr. K. Nagaiah, Chief Scientist, CSIR - Indian Institute of Chemical Technology, Hyderabad; Dr. Satyanarayana Thirunahari, Senior General Manager - Process Safety & Engineering, Laurus Labs; and Yadavendra Shalgaonkar, Assistant General Manager - Tube Sales, Alleima India
US formulations grew 11% to Rs. 564 crore as Alembic enters US branded pharmaceuticals market with launch of Pivya
Analysts expect modest revenue growth but pressure on profitability in the March quarter
Call it one of the most striking turnarounds in the Indian pharma sector this fiscal year
Building a transparent, data-driven supply chain and self-reliant API ecosystem remains critical to reducing import dependence
Reaffirms Lupin’s commitment to sustainable resource management
By applying digital technologies, pharma companies can significantly improve their operational and decision-making capabilities
The department will soon release a policy to catalyze research & development and innovation in the pharma- Medtech sector in India
The resilient attitude of Indian pharmaceutical companies coupled with quick innovative solutions has ensured consistency in supply chains amid unprecedented challenges
Subscribe To Our Newsletter & Stay Updated
